Loading
Life sciences · Journal article
Biomedicines · November 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Youth-onset type 2 diabetes (Y-T2D) is a heterogeneous cardiometabolic disease in which pubertal insulin resistance, limited β-cell reserve, obesity-related metabolic dysfunction, genetic susceptibility, early-life exposures, and barriers to care converge. This structured narrative review synthesizes evidence from pediatric randomized trials, longitudinal cohorts, clinical guidelines, and studies of metabolic bariatric surgery in adolescents identified through database searches updated to 15 October 2026. Pediatric evidence shows limited durability of metformin-based therapy in the selected TODAY population and continued β-cell deterioration in RISE, which included youth with impaired glucose tolerance and those with recently diagnosed type 2 diabetes. Contemporary trials demonstrate clinically important short-term glycemic efficacy for GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide; among pediatric type 2 diabetes trials, only tirzepatide has produced a large concurrent reduction in BMI. However, differences in baseline HbA1c, background therapy, trial duration, estimands, and rescue-treatment rules preclude indirect efficacy rankings. Long-term effects on β-cell preservation, growth, puberty, bone and reproductive health, and cardiovascular or kidney outcomes remain unproven. Clinical priorities therefore include accurate classification, prompt treatment intensification, obesity-directed care, complication surveillance from diagnosis, and active mitigation of psychosocial and access barriers. This review provides an evidence-tiered interpretation of disease biology and a practical treatment-sequencing framework that distinguishes established pediatric findings from adult or experimental extrapolation.